Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gender and Survival in Patients with ET

Am J Hematol; ePub 2017 Aug 28; Tefferi, et al

Women with essential thrombocythemia (ET) live longer than their male counterparts, according to a study involving nearly 1,500 individuals. In fact, gender might carry more weight than thrombosis history when predicting overall survival. One group of participants were from the Mayo Clinic (n=904). They had ET and were a median of 58 years of age. ~Two-thirds were female. Investigators analyzed them by international ET prognostic (IPSET) score, and then confirmed findings in a validation cohort. Among the results:

  • Males were 60% more likely to experience shortened survival.
  • Patients ≥60 years of age and those with leukocyte count ≥11 × 10(9)/L were also more likely to experience such.
  • The findings were confirmed in the validation cohort.
  • The survival disadvantage in men was highest in patients in the IPSET high risk category, and those >60 years of age.
  • Thrombosis history was not a significant predictor after multivariable analysis.

Citation:

Tefferi A, Betti S, Barraco D, et al. Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. [Published online ahead of print August 28, 2017]. Am J Hematol. doi:10.1002/ajh.24882.

This Week's Must Reads

Widespread Zika screens not cost effective, Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977

New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

Good ALL outcomes in Down syndrome children, Maloney K et al. ASPHO 2018, annual meeting of the American Society of Pediatric Hematology/Oncology Abstract PP 2001

Reducing morbidity in postpartum hemorrhage, Smith R et al. Annual clinical and scientific meeting of the American Society of Obstetricians and Gynecologists 2018, Abstract 26R.

In sickle cell, start hydroxyurea in infancy, Schuchard S et al. ASPHO 2018, poster # 342 Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057

Must Reads in Thrombosis

New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

Increase kidney function monitoring if INR exceeds 4.0, Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.

2 approaches to diagnosing heparin-induced thrombocytopenia, Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103

VTE prophylaxis unaddressed in acutely ill patients, Amin A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 51.

Warfarin users take 10 other drugs on average, Jacobson A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018. Poster 2